KDM6A and non-small cell lung carcinoma: Thus, we speculated that UTX, which is considered as an oncogene in NSCLC, is expected to be a target for the treatment of some NSCLC cases that lack specific targeting treatment, and the combination of UTX inhibitor and TKIs may have positive effect on EGFR mutant NSCLC.